Study of drugs Targeting Mitogen-Activated Protein Kinase Pathway in Gastrointestinal Cancer

What is the Purpose of this Study?

If you choose to join this study, you will:
- Take the study drug (ERAS-007) in combination with other drugs, which will depend on the type of mutations your cancer has
- Have blood draws
- Give urine samples
- Have regular CT or MRI scans
- Have other tests done during your clinic visits

What is the Condition Being Studied?
Colorectal Cancer and Pancreatic Cancer

Who Can Participate in this Study?

Adults with colorectal cancer who:

- Have KRAS or NRAS mutations

- Able to swallow oral medication.

- Do not have a history of HIV infection, hepatitis B virus, or hepatitis C virus.

Age Group
Participating Institutions

What is Involved?

We are doing this study to see if an experimental drug called ERAS-007 is a safe and effective treatment for your cancer when given in combination with other cancer therapies.

Study Details

Full Title
[ERAS-007-03] A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Principal Investigator

Protocol Number

View on